Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) EBITDA Margin (2024 - 2025)

Indivior Pharmaceuticals has reported EBITDA Margin over the past 2 years, most recently at 22.63% for Q4 2025.

  • Quarterly results put EBITDA Margin at 22.63% for Q4 2025, up 724.0% from a year ago — trailing twelve months through Dec 2025 was 15.56% (up 1195.0% YoY), and the annual figure for FY2025 was 21.15%, up 1795.0%.
  • EBITDA Margin for Q4 2025 was 22.63% at Indivior Pharmaceuticals, up from 13.69% in the prior quarter.
  • Over the last five years, EBITDA Margin for INDV hit a ceiling of 22.63% in Q4 2025 and a floor of 32.44% in Q2 2024.